AGM
KIN

Alpine Global Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Alpine Global Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,413
Closed -$51K – 933
2015
Q2 		$51K Buy
+7,413
New +$52.6K 0.01% 776

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alpine Global Management's KIN Position: Q3 2015 in Review

Alpine Global Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2015, closing a stake of 7,413 shares — an estimated $51K sold.

Alpine Global Management first reported a position in KIN in Q2 2015 and held it in 1 quarter. The position peaked at $51K in Q2 2015. 45 funds tracked by Wall St. Rank hold KIN as of Q3 2015.

  • Alpine Global Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2015 after selling out during the quarter.
  • Alpine Global Management sold 7,413 Kindred Biosciences, Inc. shares in Q3 2015, an estimated $51K.
  • Alpine Global Management first reported a position in Kindred Biosciences, Inc. in Q2 2015 and held it in 1 quarter.
  • Alpine Global Management's Kindred Biosciences, Inc. position peaked at $51K in Q2 2015.
  • 45 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2015.

Based on Alpine Global Management's 13F filing for Q3 2015, filed 10 Nov 2015.